Novartis sells phase 3 rare disease drug to Pharming

Pharming has licensed late-phase rare genetic disease treatment leniolisib from Novartis for $20 million (€17.9 million) upfront. The immunomodulator could come to market in activated PI3K-delta syndrome in the second half of 2021.